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Abstract
Most RNA viruses lack the mechanisms to recognize and correct mutations that arise during genome replication, resulting in
quasispecies diversity that is required for pathogenesis and adaptation. However, it is not known how viruses encoding
large viral RNA genomes such as the Coronaviridae (26 to 32 kb) balance the requirements for genome stability and
quasispecies diversity. Further, the limits of replication infidelity during replication of large RNA genomes and how
decreased fidelity impacts virus fitness over time are not known. Our previous work demonstrated that genetic inactivation
of the coronavirus exoribonuclease (ExoN) in nonstructural protein 14 (nsp14) of murine hepatitis virus results in a 15-fold
decrease in replication fidelity. However, it is not known whether nsp14-ExoN is required for replication fidelity of all
coronaviruses, nor the impact of decreased fidelity on genome diversity and fitness during replication and passage. We
report here the engineering and recovery of nsp14-ExoN mutant viruses of severe acute respiratory syndrome coronavirus
(SARS-CoV) that have stable growth defects and demonstrate a 21-fold increase in mutation frequency during replication in
culture. Analysis of complete genome sequences from SARS-ExoN mutant viral clones revealed unique mutation sets in
every genome examined from the same round of replication and a total of 100 unique mutations across the genome. Using
novel bioinformatic tools and deep sequencing across the full-length genome following 10 population passages in vitro, we
demonstrate retention of ExoN mutations and continued increased diversity and mutational load compared to wild-type
SARS-CoV. The results define a novel genetic and bioinformatics model for introduction and identification of multi-allelic
mutations in replication competent viruses that will be powerful tools for testing the effects of decreased fidelity and
increased quasispecies diversity on viral replication, pathogenesis, and evolution.
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Introduction
Observations of RNA viruses have led to the conclusion that
they have error-prone polymerases and do not have RNA
proofreading functions [1], resulting in low replication fidelity
allowing for rapid evolution and adaptation to new environments.
Thus, RNA virus populations have been described as quasispecies,
a cloud or assemblage of wild-type (WT) and mutant genomes that
exist at a mutation-selection equilibrium [2,3,4]. Recent studies
have shown that virus diversity is essential for adaptive evolution
and the capacity to cause disease [5,6,7]. Although the extreme
genetic variability of RNA viruses is undoubtedly effective for
adaptation, it also renders them susceptible to drug-induced
population extinction by mutagenesis [2,8,9,10]. Thus, identifica-
tion and characterization of factors that directly mediate or
regulate replication fidelity are critical to understanding RNA
virus replication, pathogenesis, and evolution while providing new
avenues for intervention and control.
Coronaviruses (CoVs) are positive-sense RNA viruses that
include severe acute respiratory syndrome CoV (SARS-CoV).
CoVs have the largest genomes of any known RNA viruses,
ranging from 26 to 32 kb in size. Assuming that a fixed optimal
mutation rate (e.g., one mutation per genome per replication
cycle) applies to all RNA viruses irrespective of genome size, then
viruses with larger genomes must have higher replication fidelity as
they have more opportunity for error in each replication cycle. In
this light, it has been proposed that CoVs may have reached the
size limit for a replicating RNA molecule and thus must have
higher replication fidelity than RNA viruses with smaller genomes.
In turn, this has led to the hypothesis that CoVs perform RNA-
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dependent RNA proofreading during replication [11]. CoVs
express up to 16 nonstructural proteins (nsps) that are translated
from the input positive-sense RNA genome and processed from
polyprotein precursors by two or three viral proteinases. The CoV
nsps include proteins shown in vitro to have enzymatic activities
consistent with roles in RNA synthesis or modification, including:
RNA-dependent RNA polymerase (RdRp; nsp12), RNA primase
(nsp8), helicase-NTPase (nsp13), exoribonuclease (ExoN; nsp14),
endoribonuclease (EndoU; nsp15), RNA 29-O-methyltransferase
(MT; nsp16), and RNA cap N7-methyltransferase activity (nsp14)
[12,13,14,15,16,17]. It has been proposed that multiple CoV nsps
interact for RNA modifications including error recognition and
repair, but this has yet to be tested in defined biochemical systems.
The nsp14 exoribonuclease is present in all CoVs, and was
predicted based on identification of motifs of the DEDD
superfamily of 39-to-59 exonucleases, which includes DNA
proofreading enzymes [17,18]. Homologs of nsp14-ExoN are
present in the large RNA genomes of toroviruses (28 kb) and
roniviruses (26 kb), but not in the smaller genomes of arteriviruses
(12–16 kb) nor in any RNA virus family outside the order
Nidovirales [11]. Recombinant purified SARS-CoV nsp14 has in
vitro 39-to-59 exoribonuclease but not exodeoxyribonuclease
activity, and alanine substitutions of the DEDD residues block
activity [16,19]. We engineered and recovered viable DEDD-to-
AADD and DEDD-to-DEDA mutants of murine hepatitis virus
(MHV-A59) nsp14-ExoN, and partial genome sequencing dem-
onstrated that ExoN mutant viruses had 15-fold increased
accumulation of mutations across the regions analyzed compared
to wild-type (WT) MHV during replication in culture [20]. This
result, along with the similarity to cellular DNA and RNA
proofreading exonucleases suggested that nsp14-ExoN may
directly mediate or regulate RNA error prevention or repair. It
is unknown whether ExoN is critical for replication fidelity in all
nidoviruses possessing nsp14 or homologs (coronaviruses, roni-
viruses, and torovirurses). Further, it is unknown whether high
mutation rates are constitutively maintained during virus popula-
tion passage and if the rapidly accumulating mutations impair
replication fitness. Determination of mutation rates and quasis-
pecies diversity, as well as the impact on virus fitness and
pathogenesis, requires analysis of massive genome sequence
datasets of replication fidelity mutants and WT viruses during
single rounds of replication and during longitudinal passage. This
in turn requires new approaches to quantitate and compare
diversity from total populations. The advent of next-generation
deep sequencing methodologies allows generation of millions or
billions of bases in a single experiment, but analysis and
interpretation of these data are still a nascent science.
In this study we report the analysis of viable SARS-CoV mutant
viruses containing inactivating substitutions in the nsp14-ExoN
DEDD motif I (AADD) (S-ExoN1). Comparison of the growth and
complete genome sequences of plaque isolates of wild-type SARS-
CoV (SARS-WT) and S-ExoN1 demonstrates that all S-ExoN
mutant viruses have similar impaired growth compared to SARS-
WT, and that inactivation of ExoN results in a 21-fold decrease in
replication fidelity compared to SARS-WT. Thus, ExoN is not
required for SARS-CoV replication in culture but is required for
high-fidelity replication. We performed growth analysis and deep
sequencing of SARS-WT and S-ExoN1 population viruses
obtained during serial passage in culture, and analyzed massive
sequence datasets using newly developed methods for quantifying
deviation in a population at each genomic nucleotide position.
The results show greater diversity within the S-ExoN1 mutant
viruses than SARS-WT at all passages. The profound difference in
replication fidelity between S-ExoN1 and SARS-WT viruses, in
combination with new quantitative methods for comparison of
consensus genomes and total population diversity, will allow direct
testing of the impact of decreased fidelity and increased diversity
on replication, pathogenesis, adaptation, and fitness of coronavi-
ruses. The experiments described also have identified an extensive
library of mutations and mutation sets that can be tested for
replication effects, epistatic interactions, and impact on virulence
and attenuation.
Materials and Methods
Cells and viruses
VeroE6 cells (Vero) were maintained in minimal essential
medium (Invitrogen) containing 10% FBS, supplemented with
penicillin, streptomycin, and amphotericin B. SARS-CoV Urbani
strain (hereafter, SARS-CoV) wild-type and mutant viruses were
propagated and assessed by plaque assay on Vero cells. All
incubations of cells and virus were at 37uC in a 5% CO2
atmosphere. All viral studies were performed in certified BSL3
laboratories and exclusively within biological safety cabinets using
protocols for safe study, maintenance, and transfer of SARS-CoV
that were reviewed and approved by the Institutional Biosafety
Committees of Vanderbilt University.
Generation of SARS-CoV and ExoN mutant viruses
Viruses containing PCR-generated mutations within the viral
coding sequence were produced using the SARS-CoV assembly
strategy with the following modifications [21,22,23]. The active-site
residues of the DEDD ExoN motifs are located in the SARS-CoV
cDNA fragment D. The DE residues in ExoNmotif 1 were changed to
AA using the following primers: GCGTGGATTGGCTTTGCCG-
TAGCCGGCTGTCATGCAACTAG and CTAGTTGCATGA-
CAGCCGCCTACGGCAAAGCCAATCCACGC. The D residue
in ExoN motif 3 was changed to A using the following primers:
GGCTAGTTGTGCCGCTATCATGACTAGATGTTTAGCAG-
TCC and GGACTGCTAAACATCTAGTCATGATAGCGGCA-
CAACTAGCC. Briefly, digested, gel-purified fragments were simul-
Author Summary
Quasispecies diversity is critical to virus fitness, adaptation,
and pathogenesis. However, the relationship of fidelity to
population diversity is less studied because viral systems
with engineered differences in fidelity and bioinformatic
methods that robustly measure and compare fidelity and
diversity during replication and passage have not been
available. Coronaviruses contain the largest and most
complex RNA genomes, and encode multiple novel
replicase nonstructural proteins (nsps). We previously
demonstrated that murine hepatitis virus nsp14-exonucle-
ase (ExoN) activity is required for replication fidelity. In the
present report we have generated nsp14-ExoN inactivation
mutants of SARS-coronavirus (S-ExoN) that have stable
growth defects and dramatically decreased replication
fidelity during replication in culture. We used the S-ExoN
mutant viruses to define the diversity and stability of the
genome during replication and passage, and to test the
capacity of deep sequencing to track virus population
diversity over time. The experiments demonstrate that
viable S-ExoN mutants accumulate large numbers of
predominantly unique mutations across the genome,
and that increased diversity is continuous over passage.
The results establish methods for direct comparison of
consensus genome sequences with total population
diversity and the impact on viral growth and adaptation.
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taneously ligated together. Transcription was driven using a
T7 mMessage mMachine kit (Ambion), and RNA was electroporated
into Vero cells. Virus viability was determined by CPE (cytopathic
effect, in this case cell rounding and detachment), and progeny viruses
were passaged at low multiplicity of infection (MOI). RNA was
recovered from infected cell monolayers using TRIzol (Invitrogen)
according to the manufacturer’s instructions, and retention of
introduced mutations was verified by RT-PCR and DNA sequencing.
Viral growth and plaque assays
Vero cells were infected at an MOI of 0.1 or 0.01 PFU/cell.
After 1 h at 37uC, the inocula were removed, and cells were
washed three times and supplemented with prewarmed medium.
Samples were taken at each time point and replaced with the same
volume of prewarmed medium, then frozen. To determine viral
titer, samples were serially diluted, inoculated onto Vero cell
monolayers in 6-well plates for 1 h, and overlaid with complete
medium plus 1% agar. Plaques were visualized between 48–52 h
p.i. by neutral red staining (Sigma) or without staining by using a
light box, then counted and titers calculated. For S-ExoN1, we
attempted to use P4 virus stocks corresponding to the P3 genomes
that were sequenced using the Sanger method. However, storage
and freeze-thawing of P3 plaque clone agar plugs resulted in loss of
or greatly diminished infectivity of all S-ExoN1 clones used for
Sanger sequencing (and ,50% of all S-ExoN1 clones tested)
except for P3 c53. Thus, with the exception of c53, the other four
S-ExoN1 clones tested for growth were independent of those
sequenced.
Sanger (dideoxy) sequence analysis of complete viral
genomes
Online random number generation software (http://www.
randomizer.org) was used to choose which SARS-WT and S-
ExoN1 clones (from 60 clones per virus) to sequence using the
Sanger (dideoxy) method, resulting in selection of the clones
indicated in Figure S1. Vero cells in 25-cm2 flasks were infected
with virus from solubilized agar plugs for 30–41 h p.i., medium
was discarded, and cells were lysed and total cellular RNA
extracted using TRIzol reagent. 200 picograms of RNA were
subjected to RT-PCR with SARS-CoV-specific primers using a
OneStep RT-PCR kit (Qiagen) in 96-well plates and the following
thermal cycling conditions: 50uC630 min, 95uC615 min, then 5
cycles of 94uC630 sec, 40uC630 sec, 72uC61 min, followed by
30 cycles of 94uC630 sec, 55uC630 sec, 72uC61 min, and a final
extension of 72uC610 min. Entire genomes were amplified as 96
partially overlapping amplicons ranging from 0.4 to 0.8 kbp.
Primers were designed using high-throughput primer design
software, and primer sequences are available upon request [24].
Each PCR primer included an 18-nt M13 sequence tag (forward
primers, TGTAAAACGACGGCCAGT; reverse primers, CAG-
GAAACAGCTATGACC) for DNA sequencing. For some
samples, sequence closure required RT-PCR reactions using
additional primer pairs. Amplicons were purified from unincor-
porated nucleotides and primers either by treatment with
exonuclease I and shrimp alkaline phosphatase (USB Corp.) or
by electrophoresis and purification from agarose gels. Bulk
(uncloned) purified cDNA was directly subjected to automated
dideoxy DNA sequencing on a 3730 ABI Sequencer (Applied
Biosystems). SeqMan (DNASTAR, Inc.) and the Elvira suite
(http://elvira.sourceforge.net) were used for preliminary and final
sequence assemblies, respectively. Finished sequences required a
minimum of 2-fold amplicon coverage and a total of 4-fold
sequence coverage across the entire genome. Note that the
requirement for 2-fold amplicon coverage meant that all single-
nucleotide polymorphisms (SNPs) were confirmed from indepen-
dent RT-PCR reactions. GenBank accession numbers are
provided in Table S1.
Mutation rate determinations
The mutation rate (m) was calculated using the formula m=
number of substitutions/number of nucleotides sequenced/
number of replication cycles. For these calculations, only single-
nucleotide substitutions that were unique to individual viral clones
were included, while shared mutations and indels were excluded.
Based on growth analyses, we estimated that one replication cycle
was equivalent to 12 h for SARS-WT and S-ExoN1. The total
numbers of cycles from initiation of infection of P1 through RNA
harvest at the end of the P3 expansion step were 15 and 24.25 for
SARS-WT and S-ExoN1, respectively. The relatively long
duration of the initial virus recovery from cDNA clones at P0
(96 or 180 h for SARS-WT and S-ExoN1, respectively) was
excluded from determination of number of replication cycles since,
assuming that the P1 founder plaque clones originated from a
single genome and assuming no back mutation, mutations unique
to each clone must have accumulated after P0. An additional
assumption was that mutation rates were constant across all
passages. Mutation count data for WT and nsp14-ExoN mutants
of MHV were from Eckerle et al., 2007 [20]. Data from MHV
ExoN1 and ExoN3 (M-ExoN1 and M-ExoN3, previously
designated rExoN1 and rExoN3) were pooled (M-ExoN1/3). All
SNPs in each M-ExoN1/3 clone were unique to that clone, so for
M-ExoN1/3 the rates of accumulation of total and unique
substitutions were identical. For calculations of substitutions/
genome/cycle, genome lengths were 29,727 nt for SARS-CoV
and 31,335 nt for MHV, corresponding to the length of our
cloned viral genomes and excluding the length of the 39-terminal
poly(A) tail. MHV genomes were not completely sequenced, but
rather mutation count data from regions a-c (defined in [20])
totaling 20,163 nt for each viral clone were pooled for each M-
ExoN1/3 and MHV-WT clone.
Passage series
Flasks of electroporated cells with evidence of CPE were
designated as passage 0 (P0) and subjected to a plaque assay.
Individual plaques were isolated and expanded on fresh cells,
generating stocks that were titered and used to initiate the passage
experiment. Three different P1 plaque isolates were used for each
virus, SARS-WT (c1, c2, and c3) and S-ExoN1 (c5, c8, and c13),
and these were the first three WT clones that were isolated and the
S-ExoN1 clones with the lowest clone numbers that produced
CPE when transferred to a flask of fresh cells. For SARS-WT, P1
c1 was the same parental clone used to generate the P3 plaque
clones subjected to Sanger sequencing, whereas P1 c2 and c3 were
unrelated to the P3 clones used for Sanger sequencing. For S-
ExoN1, we attempted to use the parental P1 c3 that was used for
Sanger sequencing to initiate a passage lineage, however, storage
and freeze-thawing of plaque clone agar plugs resulted in loss of
infectivity. Thus, P1 c5, c8, and c13 were independent of the P3
clones used for Sanger sequencing. The passage experiment
consisted of plating Vero cells in 25-cm2 flasks the day before
infection. Immediately prior to infection, medium was replaced
with fresh medium, and then cells were infected at an MOI of 0.1
PFU/cell. Following 24-h incubation, the supernatant was
removed, filtered, aliquoted and frozen. Cells were lysed using
TRIzol according to manufacturer’s instructions and the lysates
frozen. A small sample of each virus from each passage was
thawed and the titer determined by plaque assay. Then the
appropriate volume of virus was used to initiate the next passage,
Reduced Replication Fidelity of SARS-ExoN Mutants
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maintaining an MOI of 0.1 at all passages. SARS-WT and S-
ExoN1 clones were each subjected to 20 passages.
Deep sequence analysis of viral genomes
RNA samples from P1’, P5’, and P10’ in the population passage
series were subjected to reverse transcription using Superscript III
reverse transcriptase (Invitrogen) and random hexamers at 50uC
for 1 h. Entire genomes were amplified from first-strand cDNA by
40 PCR cycles as 13 partially overlapping amplicons ranging from
2.4 to 2.6 kbp (primer sequences available upon request). Thermal
cycling conditions were: 95uC62 min followed by 40 cycles of
95uC645 sec, 52 or 54uC (depending on the primer pair)645 sec,
and 72uC63 min, concluding with a final extension of 72uC65 -
min. Amplicons were purified from agarose gels using Wizard SV
Gel and Clean-Up kit (Promega) and concentration and purity
determined using an ND-1000 spectrophotometer (Nanodrop
Technologies, Inc.). For each sample, the 13 amplicons were
pooled in equimolar amounts to a final concentration of 125 ng/
ml, and 2 mg were used for sample preparation, cluster generation,
and multiplexed sequencing using standard commercial kits and
protocols for single-end reads (Illumina). For multiplexed sequenc-
ing, individual libraries were constructed using genomic adaptor
‘‘barcodes’’ that contain 6-base index sequences and were unique
for each sample. Pooled samples were loaded in a single lane of a
flow cell and sequencing was performed on a Genome Analyzer II
device (Illumina) [25].
SNP calling in Sanger sequences
Complete Sanger genome sequences were aligned against a
reference genome using ClustalW or the Align to Reference tool in
MacVector 10.0 (MacVector, Inc.) with default parameters. The
two reference genomes used throughout this study were the
sequence of the infectious SARS-WT cDNA clone with or without
the engineered ExoN1 mutations, as appropriate. SNPs were
identified by visual inspection of the multiple sequence alignments.
Positions with ambiguous nucleotide codes due to signals for
multiple bases at the same position in the experimental Sanger
sequences were not considered mutations for this study.
Mapping of Illumina sequencing reads and identification
of SNPs
RazerS software [26] was used to map each 75-base sequencing
read uniquely to the genome, initially allowing up to nine
mismatches (88% identity) as well as insertions and deletions
(indels). Position profiles and SNPs from the read mapping were
then generated for each sample. A position profile is defined for
each sample as the observed nucleotide distribution at each
position along the reference genome, based upon the reads that
mapped for that sample. Position profiles for each sample were
also generated separately for forward reads and reverse reads, as
well as bi-directionally. Before generating the position profiles,
several quality filters were applied to the data. First, the last five
bases of each read were trimmed to remove low quality bases that
tend to be more frequent toward the end of each read. Second,
any bases from reads that overlapped with a PCR primer region
were trimmed. Third, any base with a quality value ,29 was
removed from the position profiles. Finally, for the bidirectional
position profiles, bases that had ,20x coverage in either read
direction were excluded. For the determination of SNPs, two
additional filters were imposed: 1) at least 20 combined reads from
both directions must support the SNP, and 2) the SNP must occur
in at least 5% of the reads in each direction. After initial analysis, it
was determined that reads with .3 mismatches should be
excluded to further reduce the noise level attributable to mapping
errors. The list of SNPs identified was unaffected by this additional
filter, further supporting the idea that the extra mismatches could
be attributed to random mapping errors.
RMSD calculations and plots
To measure the differences in nucleotide distributions between
two samples, the root mean square deviation (RMSD) between
them was calculated. Using the position profile that was
generated for each sample based on the RazerS read mappings,
positional nucleotide distributions were computed and then
compared using a modified version of the standard RMSD
formula [27]:
RMSD X ,Yð Þi~
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiP
p~ A,T ,G,C,{f g P Xi,p
 
{P Yi,p
  2
5
s
.P[Xi,p]
and P[Yi,p] are the probabilities of nucleotide, p, at position i, for
the sample X and Y, respectively. The nucleotide, p, is an element
of the nucleotide set {A, T, G, C, –}, where the ‘–’ character,
represents a gap that was necessary to align the sequences within
the sample against the reference. The position, i, ranges from 1 to
the length of the gapped alignment, L. The number of indels that
were necessary to align the sequences in the multiple sequence
alignment were also included for each position. The denominator
within the square root operator, 5, is the number of possible
nucleotides plus the gap.
The minimum RMSD value is 0 when the distributions of
nucleotides are identical between the two genomes for a specific
position. The maximum value of 0.632 is generated if the allele of
one sample is completely different than the second sample, for
example, if sample X consists of 100% T’s and sample Y consists
of 100% G’s. Summary RMSD values between two samples were
generated by computing the arithmetic mean of each RMSD
value for every position along the length of the genome, L. The
95% confidence intervals were computed for the summary RMSD
values using the bootstrap method with a sample size of L and
10,000 trials.
The RMSD plot visualizes the differences between the
positional nucleotide distributions of one or more samples and
the reference genome. The RMSD plot represents the genomic
position along the x-axis and the computed RMSD value for each
nucleotide position from the reference along the y-axis. Each
colored glyph on the RMSD plot corresponds to a different sample
that has been compared to the reference.
Statistical analyses
Two-tailed Wilcoxon rank-sum tests and Pearson’s chi-square
tests were performed using STATA 9.1 software (StataCorp,
College Station, TX). For all statistical tests a P value of,0.05 was
considered significant.
Results
SARS-CoV nsp14-ExoN mutants are viable but growth
impaired
To determine whether nsp14-ExoN is required for replication of
SARS-CoV, the conserved ExoN active-site residues of motif I,
Asp90 and Glu92, or motif III, Asp273, of nsp14 were substituted
with alanine in viruses S-ExoN1 and S-ExoN3, respectively
(Figure 1, Table 1). The same mutations have been shown to
ablate 39-to-59 ExoN activity of purified SARS-CoV nsp14 in vitro
[16]. All mutations were engineered into the in vitro-assembled
full-length cDNA of recombinant SARS-CoV strain Urbani,
followed by electroporation of Vero cells with in vitro-transcribed
Reduced Replication Fidelity of SARS-ExoN Mutants
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viral genome RNA and nucleocapsid (N) protein transcripts. For
both constructs, characteristic SARS-CoV-induced cytopathic
effect (CPE) was observed in electroporated cells, and culture
medium contained infectious virus as determined by plaque assay.
Virus in the culture medium of electroporated cells (passage 0, P0)
was used to infect cells for RNA isolation and plaque isolation of
viral clones at P1 (Figure 2A). Sequence analysis of RT-PCR
products amplified from viral RNA from cells infected with P1
plaque isolates showed that all four S-ExoN1 clones and three of
four S-ExoN3 clones retained the engineered mutations. One S-
ExoN3 clone isolated from a rare large plaque contained a same-
site reversion (GCC-Ala to GAC-Asp) at residue 273, whereas all
S-ExoN1 plaques and the majority of S-ExoN3 plaques were small
or medium in size compared to the large plaques generated by
wild-type SARS-CoV (SARS-WT; data not shown). Retention of
motif I mutations was also verified by sequence analysis of two
independent P1 stocks of S-ExoN1 that had not been subjected to
plaque isolation. Since the motif I mutations appeared more stable
than those of motif III, S-ExoN1 was used in all subsequent
experiments. Thus, intact ExoN active-site residues in motifs I and
III are not required for SARS-CoV replication in culture but are
required for efficient plaque development.
To determine whether substitution of ExoN active-site residues
altered viral replication, we performed growth assays in Vero cells
using P4 stocks of SARS-WT plaque clones 14 and 21 (c14 and
c21) and S-ExoN1 c53 at a multiplicity of infection (MOI) of 0.1
plaque-forming units (PFU) per cell. Growth kinetics of S-ExoN1
and both SARS-WT clones were identical for the first 20 h, after
which S-ExoN1 exhibited reduced viral titers compared to SARS-
WT. SARS-WT and S-ExoN1 achieved peak viral titers at 30–
36 hpi, although this was reduced by 4-fold for S-ExoN1
(Figure 3A). Both SARS-WT clones showed identical growth
throughout the experiment (data not shown). These results
indicate that inactivation of ExoN results in impaired replication
of SARS-CoV.
SARS-CoV ExoN mutant viruses accumulate nucleotide
substitutions across the genome
To determine whether S-ExoN1 viruses accumulated more
substitutions than SARS-WT, one P1 plaque isolate each of S-
ExoN1 and SARS-WT was expanded as a P2 stock, from which
multiple P3 plaque isolates were obtained and used to infect new
cells for isolation of total RNA (Figure 2A). The entire genome
sequences of 10 viral plaque isolates each for S-ExoN1 and SARS-
WT were determined from uncloned RT-PCR products (Table
S1). Analysis of SARS-WT identified two or three mutations in
each genome. In contrast, each of the 10 S-ExoN1 genome
sequences contained 12 to 23 non-engineered (secondary)
nucleotide substitutions in addition to the four engineered ExoN1
Figure 1. SARS-CoV genome organization and nsp14 exoribonuclease motifs. (A) SARS-CoV genome organization and ORF 1a/b
polyprotein expression. The genome is a 29.7-kb positive-sense RNA molecule that is capped (dark circle) and polyadenylated. Genes are indicated for
the replicase (ORF 1a and ORF 1b; white), structural proteins [Spike (S), Envelope (E), membrane (M), and nucleocapsid (N) proteins; black], and
accessory proteins (light gray). ORF 1b is accessed by ribosomal frameshift in the nsp12 coding sequence. The ORF 1a/b polyprotein is translated
directly from input genome RNA and processed into 16 mature nsps by two virus-encoded proteinases (gray). Nsps have predicted or demonstrated
activities as described in the text. Hel, helicase; Endo; endoribonuclease; MT, 29-O-methyltransferase. (B) Organization of nsp14 and partial sequence
alignment of representative CoV nsp14 sequences with Eschericia coli DNA polymerase III epsilon subunit (DP3E), the proofreading exonuclease
subunit of the replicative DNA polymerase (SwissProt P03007). Sequence alignment and GenBank accession numbers for the full-length CoV
genomes are as in [20]. Active-site residues of conserved motifs I to III of the DEDD superfamily are indicated in red and by amino acid position in
nsp14. A predicted zinc finger domain (Zn F) is located between motifs I and III in the viral sequences, and the predicted zinc-coordinating residues
are shown in blue type. Residues replaced with alanine are indicated by black arrows for SARS-CoV mutants S-ExoN1 and S-ExoN3.
doi:10.1371/journal.ppat.1000896.g001
Table 1. Engineered ExoN mutations.
Virus
Nucleotide
substitutionsa Codon change
Amino acid
substitutionsb
S-ExoN1 A18238C, T18239C GATRGCC Asp90Ala
A18244C, G18245C GAGRGCC Glu92Ala
S-ExoN3 A18787C, T18788C GATRGCC Asp273Ala
aNucleotide positions refer to the SARS-CoV Urbani strain complete genome
sequence (GenBank accession no. AY278741).
bAmino acid positions refer to mature nsp14 sequence (polyprotein 1ab
residues 5903-6429).
doi:10.1371/journal.ppat.1000896.t001
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point mutations (Figure 4A). The difference in non-engineered
substitution counts between SARS-WT and S-ExoN1 was highly
statistically significant (P,0.0005, Wilcoxon rank-sum test).
Mutations among different clones of SARS-WT and S-ExoN1
were classified as either common to all clones, common to multiple
but not all clones, or unique to individual clones. Analysis of the
mean substitution counts showed that, compared to SARS-WT
genomes, S-ExoN1 genomes contained 7.6-fold more total
substitutions (common plus unique) and 20.7-fold more substitu-
tions unique to individual clones (Figure 4, A and B).
Within the ,300 kb of total sequenced nucleotides for both S-
ExoN1 and SARS-WT, a total of 100 different non-engineered
mutations (99 substitutions and one deletion) were identified in the
10 S-ExoN1 genomes, whereas only seven different non-engineered
mutations (six substitutions and one deletion) were identified in the
10 SARS-WT genomes (Figure 5, Table 2). For every mutation, the
genomic position, level of conservation among clones, and predicted
coding effect are shown in Figure S1 and Tables S2 and S3. All
mutations identified in S-ExoN1 genomes occurred at nucleotide
positions distinct from those in SARS-WT genomes. For SARS-
WT, the C6122T and A10646G mutations found in all P3 clones
also were detected in P0 population virus as polymorphisms with the
wild-type reference nucleotide. None of the secondary mutations in
S-ExoN1 clones were identified in P0 population virus, suggesting
that the mutations were generated during passage and fixed in the
population by plaque isolation. Two mutations in the SARS-WT
Figure 2. Virus isolation and passage strategy. (A) The strategy
used for plaque isolation and passage to obtain stocks used in dideoxy
(Sanger) DNA sequencing and viral growth analyses. Flasks indicate
population stocks, and circles indicate plaque isolation. A single
Passage 1 (P1) plaque clone was the parent of all P3 clones used in
complete genome sequence analysis (10 clones) or growth analysis (five
clones). Clone numbers are shown. S-ExoN1 P3 clone 53 (c53) was used
in both sequence and growth analyses. The scheme shown is for S-
ExoN1 but an identical scheme was used for SARS-WT except that clone
numbers were different and P3 c21 was used in both sequence and
growth analyses. For sequencing, P3 plaque homogenates were
expanded on fresh cells and total intracellular RNA was obtained (not
shown). Genome sequences were defined as P3, whereas P4 viral stocks
were used in growth analyses. (B) Serial population passage. Passage
numbers in the serial population passage series are designated with a
prime. Three clones of SARS-WT or S-ExoN1 were isolated at P1 or P1A,
respectively, and passaged in parallel in the P1’-P20’ series. Note that
P1A in panel B and P1 in panel A are distinct plaque isolation
experiments from the same P0 stock. Viral titers were determined at
every passage in the P1’-P20’ series and next-generation sequencing
(NGS) was performed at P1’, P5’, and P10’ for one clonal lineage each for
SARS-WT and S-ExoN1.
doi:10.1371/journal.ppat.1000896.g002
Figure 3. Growth analysis of viral replication. Growth compari-
sons of SARS-WT and S-ExoN1 viruses (A), and of multiple S-ExoN1
clones and S-ExoN1 population virus (B). (A) Vero cells were infected
with SARS-WT P4 c21 and S-ExoN1 P4 c53 viruses at an MOI of 0.1 PFU/
cell. (B) Vero cells were infected with P1 population stock of S-ExoN1 or
S-ExoN1 P4 clones (c53, c62, c63, c64, and c65) at an MOI of 0.01 PFU/
cell. Samples of culture medium were obtained at 1, 4, 8, 12, 16, 20, 24,
30, 36, and 48 h p.i., and viral titers were determined by plaque assay.
Mean titers and standard deviations from triplicate infection series are
indicated for each time point.
doi:10.1371/journal.ppat.1000896.g003
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group and 16 mutations in the S-ExoN1 group were identified in
multiple genomes within each respective group. The mutations
identified in all S-ExoN1 clones or all SARS-WT clones were likely
fixed in the single P1 parent clone of each group, as was shown by
detection of the same mutations in the parental SARS-WT P1 c1
(Table S4). Mutations identified in multiple but not all S-ExoN1
clones likely arose during P1 plaque outgrowth or P2 expansion,
followed by accumulation of unique mutations in each clone after
isolation of P3 plaques.
The mutations in S-ExoN1 were distributed across the genome
(Figure 5). To determine whether the distribution of mutations was
non-random, the 29,727-nt genome was arbitrarily divided into
Figure 4. Mutation counts and rates in viral clones. Complete genome sequences were determined for 10 SARS-WT and 10 S-ExoN1 P3 viral
clones. Numbers of total (A) or unique (B) non-engineered nucleotide substitutions identified in SARS-WT and S-ExoN1 genomes are indicated. Each
circle represents the mutation count value from a single genome sequence and lines indicate mean mutation counts. Rates of accumulation of
unique substitutions per replication cycle on a per nucleotide (C) or per genome (D) basis. Mean values are plotted and error bars indicate standard
deviations. *, P,0.0005; Wilcoxon rank-sum test.
doi:10.1371/journal.ppat.1000896.g004
Figure 5. Distribution ofmutations across genomes of aggregate viral clones. Combinedmutations from 10 SARS-WT and 10 S-ExoN1 P3 viral
clones are plotted according to position in the SARS-CoV genome (drawn to scale). Non-engineered mutations are depicted as lollipops and engineered
ExoN1 mutations in nsp14 are depicted as a bent vertical line. Red, mutations common to all SARS-WT or all S-ExoN1 clones; green, mutations common
to multiple but not all S-ExoN1 clones; blue, mutations unique to one SARS-WT or S-ExoN1 clone. Filled lollipops, nonsynonymous mutations; open
lollipops, synonymous mutations; black open lollipops, mutations in non-coding regions. A 30-nt deletion in SARS-WT clone 7 that disrupts ORFs 8a and
8b and a three-nt deletion identified in S-ExoN1 clone 46 in ORF E are indicated above the lollipops by D30 and D3, respectively. All mutations identified
in SARS-WT genomes occurred at nucleotide positions distinct from those in S-ExoN1 genomes. White boxes, nsp domains encoded by ORF1. For
simplicity and because no mutations were detected in nsp11, a predicted 17-aa polypeptide that partly overlaps with the amino-terminus of nsp12,
nsp11 is not shown. Dark gray boxes, ORFs encoding structural proteins: S, Spike attachment glycoprotein; E, Envelope protein; M, Membrane protein; N,
Nucleocapsid protein. Light gray boxes, ORFs encoding group-specific (accessory) proteins.
doi:10.1371/journal.ppat.1000896.g005
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equal thirds with division points between nt 9909/9910 and nt
19,818/19,819. The 59, middle, and 39 thirds contained 29, 26,
and 44 mutations, respectively, from the aggregate clones, but the
differences were not significant (P=0.06, Pearson’s chi-square
test). When the genome was instead divided in half, no statistical
evidence was observed for non-random distribution between the 59
and 39 halves of the genome (41 and 59 mutations, respectively;
P=0.072). Distribution analyses could not be performed on
SARS-WT due to insufficient numbers of mutations in the 10
clones. While the combination of mutations from different
genomes and division of the genome for analysis both support
the hypothesis that the mutations are random, they do not
constitute proof, since epistatic interactions could potentially
influence the unique mutation sets observed in each clone. Total
non-redundant substitution frequencies (where each shared
mutation was counted only once) were 16.5-fold higher in S-
ExoN1 than SARS-WT genomes (3.34E-04 and 2.02E-05
substitutions per nucleotide, respectively, Table 2). The seven
substitutions identified in SARS-WT genomes were nonsynon-
ymous (NS), whereas the S-ExoN1 genomes had similar numbers
of NS and synonymous (Syn) substitutions as well as six mutations
in non-coding regions. Analysis of all coding regions of S-ExoN1
genomes showed that coding regions for nsp3, nsp4, nsp8, and
Spike glycoprotein regions had one or more NS mutations in every
S-ExoN1 genome (Figure S1B). For Spike alone the 20 sequenced
SARS-WT and S-ExoN1 genomes resulted in identification of 11
NS mutations in Spike that were tolerated for replication and had
not been previously reported. Coding changes also resulted in
disruptions or extensions of ORFs 8a/b in one SARS-WT clone
and ORFs 3b and 7a/b in three different S-ExoN1 clones
(Tables S2 and S3). S-ExoN1 P3 c46 had a deletion that
removed the carboxy-terminal residue Val76 of the envelope (E)
protein. Overall, the sequencing data show that engineered S-
ExoN1 mutations result in a mutator phenotype similar to that
observed for MHV ExoN mutants. These results establish that
ExoN activity is required for replication fidelity of divergent
coronaviruses.
To determine how the mutation rates compared between this
SARS-CoV study and our previous MHV study, we calculated
mutation rates for S-ExoN1 and SARS-WT and compared them
with those for M-ExoN1, M-ExoN3 and MHV-WT [20]. For
these calculations, numbers of unique substitutions in individual
viral clones were used, whereas shared substitutions and indels
were excluded. Assumptions include a constant mutation rate at all
passages, no back mutations, and a 12-h replication cycle for S-
ExoN1 and SARS-WT. S-ExoN1 had a 13-fold (P,0.0005,
Wilcoxon rank-sum test) higher substitution rate than SARS-WT
(Figure 4C). This difference is less than the 21-fold difference in
substitution frequencies because S-ExoN1 viruses were grown for
longer durations than SARS-WT at the P2 and P3 steps. For
comparison, M-ExoN1/3 had a 13-fold (P,0.01) higher substi-
tution rate that MHV-WT. This value is similar to the reported
15-fold difference in substitution frequencies because although M-
ExoN1/3 grew more slowly than MHV-WT, the total number of
replication cycles for both viruses was identical. Although the rate
for SARS-WT was 2.8-fold lower than MHV-WT, this difference
was not statistically significant.
S-ExoN1 had a 2.9-fold lower (P,0.005) substitution rate than
M-ExoN1/3. The reason for this difference is unclear. One
possibility is that SARS-CoV may have additional or more
efficient mutation correction mechanisms. An alternative expla-
nation is that the SARS-CoV study was not designed to determine
mutation rates. For example, durations of S-ExoN1 and SARS-
WT infections used for rate determination were estimates since
exact durations were not recorded. It is unclear if differences in the
virus passage and plaque isolation protocols for the two studies
contribute to differences in mutation rates, and if so, to what
extent. Yet another possibility is that approximately one-third of
each MHV genome was not sequenced, so the MHV mutation
rates may not be representative of the entire genome.
Effect of ExoN mutant virus mutator phenotype and
mutations on growth during infection and passage in
culture
To determine whether the secondary mutations generated
during S-ExoN1 replication alter growth, we compared the
replication kinetics of S-ExoN1 P1 uncloned population virus
with five S-ExoN1 P4 plaque isolates, including the completely
sequenced c53. S-ExoN1 P1 population virus and all five P4 viral
clones grew with similar kinetics and achieved equivalent peak
viral titers in Vero cells by 48 h p.i. (Figure 3B). From 12–36 h
p.i., titers of all P4 clones were equivalent or modestly reduced
compared to P1 virus. These results suggest that S-ExoN1
replication in Vero cells is unaffected by the non-engineered
mutations in viral clones or at least the cumulative effect of all
mutations in each clone (mutation set).
To determine whether replication of S-ExoN1 is stable over
time, we passaged three plaque isolates each of SARS-WT and S-
ExoN1 20 times (P1’-P20’) at the population level in Vero cells at
an MOI of 0.1 PFU/cell for 24 h (Figures 2B and 6). Overall,
mean titers of the three clones for both SARS-WT and S-ExoN1
increased over passage, and the increase was more substantial for
S-ExoN1 (,2 log10) compared to SARS-WT (1 log10) (Figure 6A).
Mean titers showed little change from P7’-P18’ for SARS-WT and
Table 2. Mutation types and frequencies.
Non-redundant mutationsb
Virus No. of clones
Total nt
sequenceda NS Syn NCR Indel Total NS:Syn Ts:Tvc
Substitution
frequencyd
SARS-WT 10 296,468 6 0 0 1 7 n.a. 1.0 2.02E-05
S-ExoN1 10 296,471 49 44 6 1 100 1.1 5.2 3.34E-04
ant, nucleotides. Values are sums for all P3 clones of each virus.
bValues are derived from the aggregate of all P3 clones for each virus and include shared and unique non-engineered mutations. Each shared mutation was counted
only once. Substitutions were categorized as NS, nonsynonymous; Syn, synonymous; or NCR, non-coding region. Indel, insertion or deletion. A T25783A mutation in S-
ExoN1 clone 34, which is Syn in ORF 3a but NS in ORF 3b, was categorized as NS here and in Figure 5.
cTs, transition; Tv, transversion.
dSubstitution frequency was calculated by dividing the sum of NS, Syn, and NCR mutations by the total number of nucleotides sequenced.
doi:10.1371/journal.ppat.1000896.t002
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P9’-P19’ for S-ExoN1. Titers of individual S-ExoN1 and SARS-
WT clones were largely non-overlapping, and all six clones
showed maximal or near-maximal titer at P20’ (Figure 6B). These
results demonstrate that population passage of both SARS-WT
and S-ExoN1 selects for increased growth during population
passage in Vero cell culture, and suggest the possibility that growth
adaptation is independent of the ExoN mutator phenotype. We
recognize that while growth assays are a good measure of relative
replication and virus production, they cannot be used to compare
virus fitness, which would require competitive coinfection and
passage [28,29]. Since S-ExoN mutants generate mutations in all
identified genomes, we would predict that any competitive fitness
experiment would be influenced - either positively or negatively –
by the decreased fidelity and increased diversity of S-ExoN
mutants arising during competitive passage. Thus, fitness exper-
iments of S-ExoN mutator mutants would need to take into
account the balance between accelerated evolution and accumu-
lation of large numbers of random mutations in individual
genomes and the total virus population. Testing of fitness for
individual mutations or groups of mutation in virus clones
(mutation sets) or cumulative mutations in a population therefore
would require recapitulation of the mutation(s) or mutation sets in
the background of WT ExoN, in order to have a more stable
genetic background during replication with fitness and selective
pressure determined by the introduced mutations and allowing
direct comparison with SARS-WT.
Deep genome sequencing reveals retention of S-ExoN1
engineered substitutions and increased mutation
frequencies across the S-ExoN1 genome during
population passage
To determine whether genetic diversity of S-ExoN1 viruses
increases over passage and whether the engineered ExoN1
mutations are retained, we employed massively parallel deep
(Illumina) DNA sequence analysis on P1’, P5’, and P10’ of S-
ExoN1 c5 and SARS-WT c1 from the serial passage experiment
described above. Total intracellular RNA from infected monolay-
ers was used for reverse transcription and amplification into 13
overlapping amplicons that were processed and subjected to deep
sequence analysis [25]. The mean sequence coverage depth
ranged from 486 to 1004 reads per nucleotide for each of the six
samples, with greatest coverage across regions of amplicon
overlap, as reported by others [30] (Figure S2). For S-ExoN1 c5
P1’, P5’, and P10’, 98.6–99.7% of sequence reads across nsp14
codons 90 and 92 contained the four engineered nucleotide
substitutions resulting in alanine substitutions. The small fraction
of reads that did not contain all four engineered mutations could
be explained by the reported ,1% error frequency of Illumina
sequencing [31]. This result demonstrates that the engineered
ExoN1 mutations are stably maintained through 10 passages and
that same-site reversion was not responsible for the observed
increased viral titers during passage.
To compare global diversity of SARS-WT and S-ExoN1, we
determined the percentage of reads with 0–3 mismatches at P1’,
P5’, and P10’. A higher percentage of reads from S-ExoN1 had
one, two, or three mismatches, whereas a higher percentage of
reads from SARS-WT had no mismatches (Figure 7A). No short
insertions or deletions were confirmed in at least 20 combined
sequence reads of both directions from any of the six samples, and
due to the short read lengths, we did not attempt to identify long
insertions or deletions. These results indicate that S-ExoN1 had
substantially greater genetic diversity than SARS-WT. To
determine and compare the distributions of substitutions across
the genome, the root mean square deviation (RMSD) between
each sample and a SARS-WT or S-ExoN1 reference sequence, as
appropriate, was calculated and plotted for every nucleotide
position at P1’, P5’, and P10’. In this analysis, the maximum
RMSD value of 0.632 indicates completely distinct single allelic
distributions, and values below 0.0125 were considered back-
ground. Each of the S-ExoN1 samples had a larger number of
points with RMSD values above background than each of the
SARS-WT samples, and this was particularly evident for points
with values of 0.3 through 0.632 (Figure 7B). These results and the
increased mean RMSD of each S-ExoN1 compared to each
SARS-WT sample (Figure 7C) indicate that the three S-ExoN1
samples have greater diversity than the three SARS-WT samples
relative to the reference sequences at P1’, P5’, and P10’. These
results are consistent with decreased replication fidelity of S-
ExoN1. RMSD analyses also demonstrated a trend of increased
diversity over passage for both viruses although the differences
between passages were not statistically significant and not as great
as those between S-ExoN1 and SARS-WT.
We next compared the numbers and patterns of points with near-
maximal to maximal RMSD values (RMSD=0.5 to 0.625) in the
RMSD plots and catalogued all dominant single-nucleotide
Figure 6. SARS-WT and S-ExoN1 titers across 20 population
passages. (A) Mean viral titers of three clones each of SARS-WT and S-
ExoN1 at passages 1’-20’. Error bars indicate standard deviations. (B)
Viral titers of individual clones of SARS-WT (closed symbols, solid lines)
and S-ExoN1 (open symbols, dashed lines) at passages 1’-20’. At each
passage Vero cells were infected at an MOI of 0.1 PFU/cell. Samples of
culture medium were collected at 24 h p.i., titered by plaque assay at
each passage, and transferred to naive cells.
doi:10.1371/journal.ppat.1000896.g006
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polymorphisms (SNPs) identified in .5% of relevant reads and
plotted their frequencies (Tables S5 and S6, Figure S3). Analysis of
numbers of points with RMSD values of 0.5 through 0.632
corresponding to SNP frequencies of .0.8, showed S-ExoN1 P1’,
P5’, and P10’ had 20, 22, and 29 SNPs in this category, respectively.
All of the SNPs with high RMSD values from P1’ were carried
through in P5’ and P10’, and those new in P5’ were carried through
in P10’ also such that S-ExoN1 P5’ gained two new SNPs relative to
P1’, and P10’ gained seven new SNPs relative to P5’, again
considering only those that met the above criteria. For SARS-WT,
the two positions with maximal RMSD values were present at all
three passages analyzed, and all other SNPs were present at much
lower frequencies. These results suggest that both substitutions
present in the entire SARS-WT population and the majority of
those in the entire S-ExoN1 population were already fixed in the
viral stocks used to initiate the passage series, likely during plaque
isolation. This interpretation is supported by the fact that the two
mutations present in .96% of reads spanning those positions from
SARS-WT P1’, P5’, and P10’ were identified by Sanger sequencing
in all 10 SARS-WT P3 genomes and the parental P1 c1 genome
(Table S2). SNPs identified by deep sequencing in S-ExoN1 P1’,
P5’, and P10’ were not identified by Sanger sequencing of P3
genomes because for S-ExoN1 independent parental clones were
used to derive the samples for Sanger sequencing and to initiate the
population passage series (Figure 2). The results further suggest that
the few points with maximal or near-maximal RMSD values unique
to S-ExoN1 P10’ are candidate adaptive mutations. In contrast, no
unique individual SNPs were detected in.40% of reads for SARS-
WT P10’, suggesting that increases in titer observed over passage
were due to different mutations in different genomes such that no
single mutant genotype achieved dominance in the population.
Discussion
In this report, we demonstrate that ExoN active-site motifs are
not required for SARS-CoV replication, but that inactivation of
ExoN results in impaired growth and a high-level mutator
phenotype that is maintained during virus passage in culture.
Together with our previous study of MHV nsp14-ExoN mutants,
the results support the theory that nsp14-ExoN serves to maintain
high-level replication fidelity, and likely serves a role in RNA-
dependent error recognition, prevention, and repair (i.e., proof-
reading) in all known viruses with RNA genomes that encode
nsp14 homologs: coronaviruses, roniviruses, and toroviruses. The
formal demonstration of RNA proofreading in coronaviruses
remains a challenge since the coronaviruses express 15 or 16
replicase/transcriptase nsps including RdRp (nsp12), RNA
primase (nsp8), endonuclease (nsp15), and RNA cap methyltrans-
ferase (nsp14, nsp16) activities in addition to nsp14 ExoN activity
[14]. Immunofluorescence, immuno-EM, and protein association
studies indicate co-localization and interactions among multiple
replicase nsps in membrane-bound complexes, and thus nsp14-
ExoN likely functions cooperatively within a multi-protein
complex for RNA initiation and elongation of RNA synthesis as
well as nucleotide recognition, excision, and repair [13,32,33].
Recent development of transient in vitro replication systems from
lysed SARS-CoV infected cells may provide an opportunity to
address these questions by direct comparison of SARS-WT and S-
ExoN1 viruses [34].
Microbiological organisms are subjected to environmental
conditions that may change drastically from host to host or within
a host. When this is considered alongside the requirement to
balance genome stability with diversity to maintain replicative
fitness, it becomes logical to propose that mechanisms for regulating
replication fidelity might have evolved. This assumption is borne out
in organisms such as Streptococcus pyogenes SF370, which exhibits a
growth-phase-dependent 100-fold variation in replication fidelity
due to reiterative excision of a prophage (SF370.4) within the
mismatch repair (MMR) gene cassette encoding mutS and mutL
[35]. SF370.4 is integrated between mutS and mutL during
stationary phase when resources are limited, blocking expression
of mutL and resulting in loss of MMR and a profound mutator
phenotype. In contrast, prophage SF370.4 is excised as an episome
during exponential phase growth allowing mutL expression, intact
MMR, and increased fidelity. The observed tolerance in S-ExoN1
replication for 21-fold changes in replication fidelity and associated
increased mutation load supports the theory that some RNA viruses
may have evolved similar strategies for regulation of fidelity. Such a
system could contribute to the stability of genome sequence during
replication under non-selective conditions but allow for rapid
adaptation to deleterious mutations or new environments. The
expression of multiple distinct proteins from the coronavirus
genome that are known or predicted to be involved in RNA
synthesis or modification also might support a regulated system for
variable replication fidelity based on virus protein precursor and
mature forms, protein concentrations, and altered virus-host protein
interactions. Although this model is speculative, it is consistent with
our results demonstrating increased diversity in S-ExoN1 genomes
and viral clones during single infections, but lack of significant
increase in diversity of S-ExoN1 populations over 10 passages. The
nsp14-ExoN mutator viruses and new bioinformatics analyses will
allow us to determine whether SARS-WT and S-ExoN mutant
viruses demonstrate changes in fidelity under a variety of conditions
including responses to different cell types, mutagens, antibodies,
antivirals, and during replication in vivo. The mutator phenotype
associated with engineered ExoN mutations constitutes a unique
property with unclear consequences for adaptation and pathogen-
esis in animals. Recently, we have recovered viable ExoN mutants
in the virulent mouse-adapted SARS-CoV – MA15 background
(MA-ExoN) [36]. Experiments in progress will test whether MA-
ExoN has altered genetic diversity, virulence, and pathogenesis in
mice in comparison with MA15, SARS-WT, and S-ExoN1.
Analysis of viral genetic diversity using massive sequence
datasets
The extent of genetic diversity in RNA virus populations has
most often been analyzed by sequencing a small number of
genomes at low coverage [37,38,39] or a small region at high
coverage [40,41,42]. The former approach has the limitation of a
lack of resolution and cannot detect variants present at low
proportions. The latter approach has the limitation of being
Figure 7. Genetic diversity of SARS-WT and S-ExoN1 from P1’, P5’, and P10’. (A) The percentage of reads within each sample that have 0-1
(left) or 2–3 (right) mismatches compared to the corresponding reference sequence are shown. (B) RMSD plots. For each SARS-WT sample (a–d) or S-
ExoN1 sample (e–h) the root mean squared deviation (RMSD) from the corresponding reference sequence is plotted for each nucleotide position in
the genome. Plots are for P1’ (a, e), P5’ (b, f), P10’ (c, g), or combined P1’, P5’, and P10’ (d, h). The maximal RMSD value of 0.632 indicates completely
different single-allelic distributions between experimental and reference sequences whereas values #0.0125 (dashed line) were considered
background. (C) Summary RMSD values between SARS-WT P1’, P5’, or P10’ or S-ExoN1 P1’, P5’, or P10’ and reference sequences were calculated by
computing the arithmetic mean of each RMSD value for every position in the genome. The 95% confidence intervals are indicated by error bars.
doi:10.1371/journal.ppat.1000896.g007
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narrowly focused and, since mutation frequencies may vary
depending on region, extrapolation to the entire genome can be
misleading. To circumvent the limitations of these approaches, we
utilized both dideoxy and deep sequencing across the entire
genome of a number of SARS-CoVs. In addition, these viruses
were generated in a controlled environment over a number of
passages at identical MOI, to examine diversity across different
virus isolates from the same passage or within the population over
serial passage. Both SARS-WT and S-ExoN1 virus titers increased
over passage in cell culture, indicating that both viruses underwent
some level of adaptation to growth in Vero cells but still
maintained differences in titer. However, passage alone did not
induce the increased mutation frequency observed in S-ExoN1
viruses, as SARS-WT was subjected to the same conditions and
exhibited few changes in the viral genome. The analyses allowed
comparison of the capacity of Sanger and deep sequencing to
define population diversity and differences in fidelity. To achieve
this goal, it was necessary to develop new methods for analysis of
massive datasets generated by deep sequencing of SARS-WT and
S-ExoN1 viral RNA. The RMSD plots in this report constitute a
novel approach to graphically visualize total diversity across a
genome. The readout can be viewed as a diversity map of
differences at every position. The RMSD diversity plots can be
visualized and analyzed at different resolutions. For example,
adaptive mutations that are selected early and that become
dominant in the population may be visualized at full resolution,
while minor or emerging mutations may be identified or predicted
by low-level changes over time by analysis of a subsection of the
RMSD plots for multiple passages. We anticipate that this
approach could be applied to evaluate deep sequence data from
any RNA/DNA virus both in vitro and in vivo.
Using these methods, we found that S-ExoN1 population
viruses had greater diversity than SARS-WT at each of the
passages analyzed (P1’, P5’, and P10’), consistent with decreased
replication fidelity indicated by Sanger sequencing of individual
virus isolates. In contrast, diversity differences between passages of
S-ExoN1 were small and not statistically significant, which we
speculate may be because most mutations did not confer sufficient
selective advantage to accumulate in substantial proportions of the
population during limited passage. Some SNPs increased or
decreased in frequency over passage. Those that increased may
confer replication or infectivity advantages, whereas those that
decreased may confer selective disadvantages. A lack of increase in
mean RMSD over passage could theoretically be caused if a
second-site mutation which complemented the fidelity defect arose
at or before P1’ of the passage series. However, it is highly unlikely
that any of the SNPs directly restored ExoN activity since titer
differences between S-ExoN1 and WT were similar throughout
the passage series. Nonetheless, one or more non-engineered SNPs
may have conferred increased titers by improving some other
aspect of the viral life cycle. Alternatively, other mechanisms could
function to limit diversity during selection for increased replica-
tion, such as recombination repair, rapid loss of highly deleterious
or lethal mutations, or other replicase proteins that independently
or cooperatively mediate error recognition and repair with nsp14.
Functions of nsp14 other than replication fidelity
In the report that first demonstrated ExoN activity from purified
SARS-CoV nsp14, it was found that substitution of ExoN active-
site residues in the full-length human coronavirus 229E (HCoV-
229E) genome prevented recovery of infectious virus, while
allowing limited genome replication and subgenomic RNA
synthesis [16]. In our study of MHV ExoN mutants we
demonstrated that those viruses had more severe growth
impairments, including a prolonged eclipse phase and larger
reductions in peak titers than S-ExoN1 [20]. Several possibilities
may explain the differences in the three viral systems. First, it is
possible that active-site substitutions result in less complete
inactivation of SARS-CoV ExoN activity. Minskaia et al. reported
low-level residual ExoN activity from purified SARS-CoV nsp14
with active-site substitutions [16], but in vitro ExoN assays have
yet to be developed using nsp14 from other CoVs. Second, unique
SARS-CoV accessory proteins or interacting cellular proteins may
mask or compensate for defects caused by ExoN inactivation.
Reports by us and others indicate that nsp14-ExoN is involved in
viral RNA synthesis (see below), so a third possibility is that RdRp
activity from SARS-CoV may be more robust than that of the
other viruses and compensates for an RNA synthesis defect
associated with inactive or less active nsp14-ExoN.
S-ExoN1 viruses maintained a growth defect relative to SARS-
WT in all passages examined, suggesting that ExoN has a non-
redundant function in coronaviruses. The primary sequence
conservation of nsp14 between SARS-CoV and MHV (57%
identical and 72% similar across the entire protein) suggest that
the function of ExoN responsible for the growth defects is the same
in both viruses. CoV ExoN is required for efficient viral RNA
synthesis as shown for MHV ExoN mutant viruses [20], a SARS-
CoV replicon harboring a deletion of nsp14 or substitution of the
ExoN motif II invariant glutamate [43], and HCoV-229E ExoN
mutant genomes in electroporated cells [16]. Thus, we speculate
that S-ExoN1 has impaired RNA synthesis (genome replication,
subgenomic RNA transcription, or both), which results in the
observed growth defects. Purified SARS-CoV nsp14 recently has
been shown to have RNA cap N7-methyltransferase activity that is
blocked by a D331A substitution, probably by preventing binding
of the methyl donor S-adenosylmethionine [14]. The D331A
substitution reduces levels of transcripts from a SARS-CoV
replicon but has no effect on ExoN activity of purified nsp14. A
D90A+E92A double substitution in ExoN motif I does not affect
methyltransferase activity in vitro. Thus, ExoN1 mutant viruses
are likely defective in a step other than cap formation. Another
possibility is that the increased mutational load due to impaired
fidelity is directly responsible for the growth defects. Finally, it is
possible that the engineered amino acid substitutions alter
interactions between nsp14 and viral or cellular proteins important
for efficient growth.
Potential implications for coronavirus resistance to
mutagens
Proposed treatment regimens for SARS include ribavirin, a
nucleoside analog that induces lethal mutagenesis of other RNA
viruses such as poliovirus, foot and mouth disease virus, hepatitis C
virus, and Hantaan virus [8,9,44,45]. Of interest, a ribavirin-
resistant RdRp mutant of poliovirus has been identified that has
increased replication fidelity [46,47,48]. The high replication
fidelity of SARS-CoV in cell culture in this study and the lower-
than-expected mutation rate of SARS-CoV in the late stage of the
2002–2003 epidemic [49,50] raise the possibility that drug-
induced lethal mutagenesis therapies may be less effective against
coronaviruses than other RNA viruses. A possible recalcitrance of
coronaviruses to lethal mutagenesis also is suggested by our
demonstration that at least in cell culture S-ExoN1 tolerates 21-
fold increase in substitution frequency, whereas a two-to-six-fold
increase in mutation frequency was sufficient to cause lethal
mutagenesis of poliovirus in cell culture [9,51]. Based on our
present results, we suggest the possibility that inhibitors of nsp14-
ExoN activity could decrease replication fidelity, and in simulta-
neous or sequential combination with an RNA mutagen, render
Reduced Replication Fidelity of SARS-ExoN Mutants
PLoS Pathogens | www.plospathogens.org 12 May 2010 | Volume 6 | Issue 5 | e1000896
SARS-CoV more susceptible to drug-induced lethal mutagenesis
[52]. The high conservation of nsp14-ExoN sequences among
coronaviruses and demonstration of mutator phenotypes in both
MHV and SARS-CoV suggest that such approaches might be
successful across coronaviruses, including viruses newly identified
and possibly emerging from bats to other animals [53].
Replication fidelity and mutation rates
The results in this study with SARS-CoV and in the previously
reported MHV ExoN mutants, describe the greatest tolerated
change in replication fidelity in infectious viruses reported for an
animal RNA virus. In addition, we predict that results for S-
ExoN1 likely under-represent the total number of nucleotide
misincorporations that occur during RNA replication, for several
experimental and biological reasons. First, these studies were
performed using infectious viruses, so all mutations must be
compatible with virus viability. Second, this subset of mutations is
further restricted by selection of those present in the most rapidly
replicating genomes in each population that result in visible
plaques or dominant populations. Third, as evidenced by the
increased virus titer during passage of both SARS-WT and S-
ExoN1, adaptive change for increased growth, and possibly fitness,
can be selected even in the setting of 21-fold decreased replication
fidelity and accumulation of mutations. Finally, calculation of
comparative mutation rates between SARS-WT and S-ExoN1 is
complicated by differences in the number replication cycles
resulting from growth defects of S-ExoN1, and consequent
increased time required for plaque development or productive
passage and cytopathic effect. Thus, we interpret our results in
terms of overall productive viral replication fidelity, rather than
intrinsic fidelity of the RNA replication machinery. Our ability to
demonstrate decreased fidelity in plaque isolates and to perform
deep sequencing on total infected cell RNA indicates that we will
be able to use this system to assess total mutations under defined
and reproducible conditions of in vitro and in vivo selection, and
thereby closely estimate mutation rates. However, direct assess-
ments of fidelity and mutation rates of the viral replication
machinery likely will require well-defined in vitro replication
systems or replicon studies, ideally where the replicase proteins are
expressed independently from an RNA species distinct from the
RNA template under investigation.
With those caveats we estimated mutation rates of SARS-WT
and S-ExoN1 and compared these with our published results of
MHV-ExoN. The S-ExoN1 and M-ExoN1/3 mutation rates of
1.2610-5 and 3.3610-5 substitutions per nucleotide per replication
cycle, respectively, from this study are within the range reported
for other RNA viruses [1,51]. In contrast, SARS-WT and MHV-
WT mutation rates of 9.0610-7 and 2.5610-6 substitutions per
nucleotide per replication cycle, respectively, calculated here are
below the expected range of,10-3 to 10-5 reported for other RNA
viruses and more similar to the rates for some small ssDNA viruses
[54,55]. While we acknowledge that it is difficult to compare
across experimental systems that use different protocols and assays,
our data are consistent with a role for nsp14 in RNA proofreading
or repair.
Insights from the mutations in S-ExoN1 mutant viruses
This study revealed several non-synonymous mutations that
have not been previously reported and that have little or no effect
on viral growth in culture. The most dramatic of these are
deletions, nonsense mutations, and missense mutations that altered
5-117 codons in ORFs 3b, 7a, 7b, 8a, and 8b, consistent with
previous reports demonstrating that the corresponding proteins
are dispensable for growth in culture and in animals [56,57]. As
predicted, no mutations were identified in RNA sequences that are
critical for subgenomic RNA transcription since efficient tran-
scription of each subgenomic RNA requires annealing of leader
and body transcription regulating sequences [58,59,60,61].
Interestingly, a T-to-C substitution was detected at nucleotide
26,354 immediately following the RNA5 (M gene) transcription
regulating sequence (nt 26,348-26,353) in S-ExoN1 P3 clone 8 by
Sanger sequencing (Table S3) and in 7% of deep sequence reads
across that position in S-ExoN1 P5’ (Figure S3). It is unknown if
T26354C alters levels of RNA5 or M protein or viral replication
but this SNP was not above the limit of detection in S-ExoN1
P10’. We observed marked bias for T-to-C and A-to-G transition
mutations in Sanger and deep sequencing data from S-ExoN1
(Table S7). These biases are consistent with the misincorporation
tendency of RdRps [46]. Only two deletions (of three or 30 nt)
were identified in this study, and no deletions and only one
insertion was found in our MHV study [20]. Since deletions or
insertions were not more or less frequent in ExoN mutant than
WT viruses, this suggests that the mechanisms such as RNA
recombination and RdRp stuttering or slippage underlying these
processes are unaltered by disruption of ExoN, although further
analysis is required to strengthen this argument. While we predict
that each of the mutations identified in P3 clones and the majority
of those identified in S-ExoN1 P1’, P5’, and P10’ populations have
little or no effect on viral growth, this prediction must be
confirmed experimentally.
Concluding remarks
Concordant results with MHV and SARS-CoV ExoN mutants
support the theory that nsp14-ExoN is involved in RNA
proofreading among group 2 coronaviruses and perhaps all
coronaviruses, and that acquisition of ExoN activity was essential
for attainment and maintenance of large nidovirus genomes. The
present study further demonstrates that the ExoN mutator
phenotype is stable over passage, generates increased population
diversity over passage, and results in the accumulation and
retention of large numbers of novel replication-tolerated mutations
and mutation sets in every sequenced genome. In this report, we
identified 100 mutations in 10 progeny of a single parental virus
after limited replication cycles. The results suggest that S-ExoN1
may allow the identification of comprehensive maps and
frequencies of mutations and mutation sets across the genome
that can be classified as neutral, complementing, or deleterious. In
combination with similar approaches with MHV-ExoN mutant
viruses, it may be possible to rapidly define genomic positions or
regions that are tolerant or intolerant of substitution in
coronaviruses, which in turn could be tested as virus family-wide
determinants of replication and pathogenesis. Finally, the
differences in mutation frequency between WT and ExoN mutants
of both SARS-CoV and MHV, in combination with the new
bioinformatic methods for analysis of deep sequence data reported
herein, may allow testing of the impact of altering the mutation-
selection equilibrium on virus fitness, adaptation, or extinction in
vitro and in vivo.
Supporting Information
Figure S1 Distribution of mutations in individual viral clones
across the genome. Mutations in individual viral clones are plotted
according to position in the SARS-CoV genome (drawn to scale).
Mutations in 10 SARS-WT (A) and 10 S-ExoN1 (B) P3 viral
clones. Mutation types are indicated using the symbol and color
scheme in Figure 5. Engineered ExoN1 mutations are depicted as
bent vertical lines. Dotted vertical lines in panel B represent
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boundaries of coding regions (omitted for ORFs 8a and 9b for
clarity).
Found at: doi:10.1371/journal.ppat.1000896.s001 (0.79 MB TIF)
Figure S2 Depth of coverage from deep sequencing. For each
nucleotide position in the SARS-CoV genome the combined
number of forward and reverse reads is plotted for SARS-WT
P109. Patterns of sequencing coverage were similar for the other
five samples. Locations of the 13 amplicons subjected to
sequencing are depicted by red boxes for comparison with the
coverage data.
Found at: doi:10.1371/journal.ppat.1000896.s002 (0.26 MB TIF)
Figure S3 Frequencies of SNPs at P19, P59, and P109. (A)
Frequencies of the 12 SNPs identified in SARS-WT and detailed
in Table S5 are shown for P19, P59, and P109. (B) Frequencies of
the 68 SNPs identified in S-ExoN1 and detailed in Table S6 are
shown for P19, P59, and P109. SNPs are ranked by nucleotide
position. SNP frequency (proportion of reads) was determined by
dividing the sum of forward and reverse reads containing a
particular SNP by the sum of forward and reverse reads spanning
the relevant position. Only dominant SNPs are shown, and SNP
frequencies ,0.05 (dashed line) were not plotted.
Found at: doi:10.1371/journal.ppat.1000896.s003 (1.79 MB TIF)
Table S1 Nucleotides sequenced by the Sanger method and
accession numbers.
Found at: doi:10.1371/journal.ppat.1000896.s004 (0.05 MB PDF)
Table S2 Non-engineered mutations identified in SARS-WT
viruses.
Found at: doi:10.1371/journal.ppat.1000896.s005 (0.06 MB PDF)
Table S3 Non-engineered mutations identified in S-ExoN1
viruses.
Found at: doi:10.1371/journal.ppat.1000896.s006 (0.09 MB PDF)
Table S4 Non-engineered mutations identified in S-ExoN1 P1
c1.
Found at: doi:10.1371/journal.ppat.1000896.s007 (0.05 MB PDF)
Table S5 SNPs identified in SARS-WT viruses at P19, P59, and
P109 by deep sequencing.
Found at: doi:10.1371/journal.ppat.1000896.s008 (0.06 MB PDF)
Table S6 SNPs identified in S-ExoN1 viruses at P19, P59, and
P109 by deep sequencing.
Found at: doi:10.1371/journal.ppat.1000896.s009 (0.09 MB PDF)
Table S7 Matrix of specific substitution types in S-ExoN1
Sanger and deep genomes.
Found at: doi:10.1371/journal.ppat.1000896.s010 (0.05 MB PDF)
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